Medical information Clinical review pending

Genetic Testing

DEAF1 Gene Mental Retardation Autosomal Dominant Type 24 Genetic Test

Genetic test using Next Generation Sequencing (NGS) to identify mutations in the DEAF1 gene, associated with certain neurological disorders and developmental delays. Confirm with the laboratory before booking.

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question

Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample: Blood sample (EDTA tube), extracted DNA, or a drop of blood on an FTA card. Confirm specific requirements with the laboratory before booking.
Results: Approximately 3 to 4 weeks. Confirm exact turnaround time with the laboratory before booking.
Preparation: A detailed clinical history of the patient is required. A genetic counseling session prior to testing is recommended to discuss the test and potential results.

Test priceKSh 40,000

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the DEAF1 Gene Mental Retardation Autosomal Dominant Type 24 Genetic Test test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

Insurer or scheme name & policy / member number
A clinician's request / prescription for the test
Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

Full name *

Mobile number *

+254

Insurer or scheme

Policy / member number (optional)

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

WhatsApp the claims team Call us

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

✓Individuals with unexplained intellectual disability or developmental delays.
✓Family history of intellectual disability or related neurological disorders.
✓Symptoms such as learning difficulties, speech delays, or behavioral issues.
✓Referral from a neurologist or geneticist.
✓Family planning and risk assessment for inherited conditions.

In plain language

What this test helps you understand

This test helps identify specific genetic mutations in the DEAF1 gene associated with intellectual disability and developmental delays. It can aid in confirming a diagnosis, understanding the genetic cause, and informing family planning and genetic counseling.

The DEAF1 Gene Mental Retardation Autosomal Dominant Type 24 NGS Genetic DNA Test is a diagnostic tool using Next Generation Sequencing (NGS) technology. It looks for specific changes (mutations) in the DEAF1 gene. This gene is linked to certain neurological conditions, including developmental delays and intellectual disability. Understanding the genetic basis of these conditions can be important for diagnosis and management. This test analyzes genetic material to identify mutations in the DEAF1 gene that may be associated with autosomal dominant forms of intellectual disability. Results can provide insights into the hereditary factors influencing neurological disorders affecting cognitive function. A genetic counselor can help interpret the results and discuss their implications for the individual and family.

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

Speak with us

We check the test and answer your questions before collection.

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

Understand your report

A counselor helps you understand the result and the next steps.

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →

PreparationA detailed clinical history of the patient is required. A genetic counseling session prior to testing is recommended to discuss the test and potential results.

SampleBlood sample (EDTA tube), extracted DNA, or a drop of blood on an FTA card. Confirm specific requirements with the laboratory before booking.

MethodologyNext Generation Sequencing (NGS) is used to analyze the DEAF1 gene for mutations.

PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.

This test specifically analyzes the DEAF1 gene. It will not detect mutations in other genes that could cause similar symptoms. A negative result does not rule out a genetic cause for the condition. Confirm with the laboratory before booking.

Read your report

What common result terms mean

TermPlain-language meaning

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.

NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.

VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.

Questions people ask

Frequently asked questions

The DEAF1 gene provides instructions for making a protein involved in brain development and function. Mutations in this gene can lead to neurological disorders.

This test looks for specific changes (mutations) in the DEAF1 gene that are known to be associated with certain types of intellectual disability.

Individuals with developmental delays, intellectual disability, or a family history of such conditions may be candidates for this test, often following consultation with a doctor or genetic counselor.

Results will indicate if specific mutations in the DEAF1 gene were found. A genetic counselor will help explain the results and their meaning for the individual and family.

A blood sample, extracted DNA, or a blood spot on an FTA card is typically required. Please confirm the exact sample type needed with the laboratory.

The turnaround time is approximately 3 to 4 weeks, but this can vary. Please confirm the current turnaround time with the laboratory before booking.

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

ACMG/AMP technical standards for sequence variant interpretation
ClinGen curation and gene–disease validity frameworks where applicable
LOINC-coded reporting for interoperable results
ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

Last updated: September 27, 2026
Medical review: not yet completed
Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →

Chat on WhatsApp